About: First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection
Creator	Schumann, Christian Abcdefg, Abcdefg, Jan Abcefdg, Franz Bock, Christopher Cdef, Reinhard Kayser, Stefan Torzewski, Jan Wagner, Florian Zimmermann Def, Oliver
Source	Medline; PMC
abstract	Patient: Male, 72-year-old Final Diagnosis: SARS-CoV-2 Symptoms: Dyspnea Medication: Standard Clinical Procedure: C-reactive protein apheresis Specialty: Immunology OBJECTIVE: Unusual clinical course BACKGROUND: C-reactive protein (CRP) plasma levels in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel viral disease, are surprisingly high. Pulmonary inflammation with subsequent fibrosis in SARS-CoV-2 infection is strongly accelerated. Recently, we have developed CRP apheresis to selectively remove CRP from human plasma. CRP may contribute to organ failure and pulmonary fibrosis in SARS-CoV-2 infection by CRP-mediated complement and macrophage activation. CASE REPORT: A 72-year-old male patient at high risk was referred with dyspnea and fever. Polymerase chain reaction analysis of throat smear revealed SARS-CoV-2 infection. CRP levels were ∼200 mg/L. Two days after admission, CRP apheresis using the selective CRP adsorber (PentraSorb(®) CRP) was started. CRP apheresis was performed via peripheral venous access on days 2, 3, 4, and 5. Following a 2-day interruption, it was done via central venous access on days 7 and 8. Three days after admission the patient was transferred to the intensive care unit and intubated due to respiratory failure. Plasma CRP levels decreased by ∼50% with peripheral (processed blood plasma ≤6000 mL) and by ∼75% with central venous access (processed blood plasma ≤8000 mL), respectively. No apheresis-associated side effects were observed. After the 2-day interruption in apheresis, CRP levels rapidly re-increased (>400 mg/L) and the patient developed laboratory signs of multi-organ failure. When CRP apheresis was restarted, CRP levels and creatinine kinases (CK/CK-MB) declined again. Serum creatinine remained constant. Unfortunately, the patient died of respiratory failure on day 9 after admission. CONCLUSIONS: This is the first report on CRP apheresis in a SARS-CoV-2 patient. SARS-CoV-2 may cause multi-organ failure in part by inducing an excessive CRP-mediated autoimmune response of the ancient innate immune system.
has issue date	2020-07-14(xsd:dateTime)
bibo:doi	10.12659/ajcr.925020
bibo:pmid	32661220
has license	cc-by-nc-nd
sha1sum (hex)	a97c5a0459e52393d8a9f7992378b11c85ff3bc0
schema:url	https://doi.org/10.12659/ajcr.925020
resource representing a document's title	First-in-Man: Case Report of Selective C-Reactive Protein Apheresis in a Patient with SARS-CoV-2 Infection
has PubMed Central identifier	PMC7377527
has PubMed identifier	32661220
schema:publication	Am J Case Rep
resource representing a document's body	covid:a97c5a0459e52393d8a9f7992378b11c85ff3bc0#body_text
is schema:about of	named entity 'Case' named entity 'Selective' named entity 'Infection' named entity 'cough' named entity 'superinfection' named entity 'lung' named entity 'oxygen saturation' named entity 'fatality rate' named entity 'Wuhan' named entity 'atavism' named entity 'plasma levels' named entity 'breathlessness' named entity 'SARS-CoV-2' named entity 'reference range' named entity 'CRP' named entity 'ICU' named entity 'CRP' named entity 'sulfasalazine' named entity 'adsorber' named entity 'complement' named entity 'Mycoplasma pneumoniae' named entity 'CRP' named entity 'Germany' named entity 'ventral' named entity 'CRP' named entity 'CRP' named entity 'acute phase protein' named entity 'SARS-CoV-2' named entity 'breathlessness' named entity 'CRP' named entity 'ARDS' named entity 'comorbidities' named entity 'plasma levels' named entity 'high-risk' named entity 'ARDS' named entity 'CRP' named entity 'Extracorporeal membrane oxygenation' named entity 'atypical bacteria' named entity 'antibodies' named entity 'high-risk' named entity 'plasma levels' named entity 'SARS-CoV-2' named entity 'creatinine' named entity '2/1' named entity 'PCR' named entity 'Antibiosis' named entity 'SARS-CoV-2' named entity 'practice guidelines' named entity 'Germany' named entity 'clarithromycin' named entity 'informed consent' named entity 'antibody' named entity 'kidney' named entity 'chronic obstructive lung disease' named entity 'infection' named entity 'Shaldon' named entity 'CRP' named entity 'ankylosing spondylitis' named entity 'CRP' named entity 'ad hoc' named entity 'CRP' named entity 'kinases' named entity 'CRP' named entity 'comorbidities' named entity 'multiorgan failure' named entity 'high-risk' named entity 'fever' named entity 'CRP' named entity 'SARS-CoV-2' named entity 'intubated' named entity 'plasma levels' named entity '5.00'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software